Effect of Mirtazapine on the quality of life of the breast cancer patients

Evaluation of the effect of Mirtazapine on the quality of life of the breast cancer patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210425051075N1

Enrollment

110

Registered

2021-10-15

Start date

2021-05-21

Completion date

Unknown

Last updated

2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: breast cancer. Condition 2: Major depressive disorder. Malignant neoplasm of breast Major depressive disorder, single episode

Interventions

Intervention 1: Intervention group: Patients will be treated with Mirtazapine 15-30 mg daily for 8 weeks. Intervention 2: Control group: Continuation of routine therapeutic care and no additional the

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Suffering from cancer Major depressive disorder according to DSM IV criteria

Exclusion criteria

Exclusion criteria: Taking sleeping pills at the same time

Design outcomes

Primary

Measure	Time frame
Quality of Life. Timepoint: Study first and 8 weeks after starting mirtazapine. Method of measurement: WHO Quality of Life Questionnaire.;Anxiety. Timepoint: Study first and 8 weeks after starting mirtazapine. Method of measurement: WHO Quality of Life Questionnaire.;Sleep status. Timepoint: Study first and 8 weeks after starting mirtazapine. Method of measurement: WHO Quality of Life Questionnaire.;Appetite status. Timepoint: Study first and 8 weeks after starting mirtazapine. Method of measurement: WHO Quality of Life Questionnaire.	—

Measure

Time frame

Quality of Life. Timepoint: Study first and 8 weeks after starting mirtazapine. Method of measurement: WHO Quality of Life Questionnaire.;Anxiety. Timepoint: Study first and 8 weeks after starting mirtazapine. Method of measurement: WHO Quality of Life Questionnaire.;Sleep status. Timepoint: Study first and 8 weeks after starting mirtazapine. Method of measurement: WHO Quality of Life Questionnaire.;Appetite status. Timepoint: Study first and 8 weeks after starting mirtazapine. Method of measurement: WHO Quality of Life Questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDanial Kamrani

Sabzevar University of Medical Sciences

danialkamrani96@gmail.com+98 51 3865 5892

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026